Influence of intrastriatal infusion of dynorphin fragments on overflow of acetylcholine and dopamine in the rat brain

International Journal of Neuroscience

Volumn 119, Issue 9, 2009, Pages 1362-1383

  Pani, Amar K ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

Author keywords

Acetylcholine; Dopamine; Dynorphin; HPLC ED; Microdialysis; Neurotransmitter

Indexed keywords

ACETYLCHOLINE; DOPAMINE; DYNORPHIN; NEOSTIGMINE;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOSE RESPONSE; MALE; MICRODIALYSIS; NEUROMODULATION; NONHUMAN; PRESYNAPTIC MEMBRANE; RAT;

ACETYLCHOLINE; ANIMALS; BRAIN CHEMISTRY; CHOLINESTERASE INHIBITORS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOPAMINE; DYNORPHINS; ELECTROCHEMISTRY; MALE; MICRODIALYSIS; MICROINJECTIONS; NEOSTIGMINE; NEOSTRIATUM; PEPTIDE FRAGMENTS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, PRESYNAPTIC; SYNAPTIC TRANSMISSION;

EID: 70350464941     PISSN: 00207454     EISSN: 15635279     Source Type: Journal    
DOI: 10.1080/00207450902955770     Document Type: Article

References (57)

1. Acri, J. B., Thompson, A. C., & Shippenberg, T. (2001). Modulation of pre- and postsynaptic dopamine D2 receptor function by the selective kappa-opioid receptor agonist U69593. Synapse, 39, 343-350.
2. Aksu, F., Holmes, B. B., & Fujimoto, J. M. (1993). Opioid antagonists: Indirect antagonism of morphine analgesia by spinal dynorphin A. Pharmacology, Biochemistry and Behavior, 45, 409-418.
3. Arenas, E., Alberch, J., Sanchez, A. R., & Marsal, J. (1990). Effect of opioids on acetylcholine release evoked by K+ or glutamic acid from rat neostriatal slices. Brain Research, 523, 51-56.
4. Berggren, A., Dahlstrom, A., Rubenson, A., & Sillen, U. (1992). Possible regulatory role of dynorphin A in the urinary bladder. Journal of Neural Transmission, 90, 33-44.
5. Chavkin, C., James, I. F., & Goldstein, A. (1982). Dynorphin is a specific endogenous ligand of the ê-opioid receptor. Science, 215, 413-415.
6. Cherubini, E., & North, R. A. (1985). Mu and Kappa opioids inhibit transmitter release by different mechanisms. Proceedings of the National Academy of Sciences, 82, 1860-1863.
7. Christensson-Nylander, I., Herrera-Marschitz,M., Staines,W., Hökfelt, T., Terenius, L., Ungerstedt, U., et al (1986). Striato-nigral dynorphin and substance P pathways in the rat. I. Biochemical and immunohistochemical studies. Experimental Brain Research, 64, 169-192. (Pubitemid 16023984)
8. Cooper, J. R., Bloom, F. E., & Roth, R. H. (2006). The Biochemical Basis of Neuropharmacology. New York: Oxford University Press, 1-51.
9. Corbett, A. D., Paterson, S. J.,McKnight, A. T., Magnan, J., & Kosterlitz, H.W. (1982). Dynorphin 1-8 and dynorphin 1-9 are ligands for the ê-subtype of opiate receptor. Nature, 299, 79-81.
10. Davis, K. L., Charney, D., Coyle, J. T., & Nemeroff, C. (2002). Neuropsychopharmacology: The Fifth Generation of Progress. Philadelphia, PA: Lippincott Williams & Wilkins, 1-2010.
11. Di Chiara, G., & Imperato, A. (1988). Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats. Journal of Pharmacology and Exerimental Therapeutics, 244, 1067-1080.
12. Duggan, A.W., & North, R. A. (1984). Electrophysiology of opioids. Pharmacological Review, 35, 219.
13. Engber, T. M., Boldry, R. C., Kuo, S., & Chase, T. N. (1992). Dopaminergic modulation of striatal neuropeptides: Differential effects of D1 and D2 receptor stimulation on somatostatin, neuropeptide Y, neurotensin, dynorphin and enkephalin. Brain Research, 581, 261-268.
14. Feldman, R. S., Meyer, J. S., & Quenzer, L. F. (1997). Principles of Neuropsychopharmacology. MA: Sinauer Associates.
15. Giuliani, S., Lecci, A., Tramontana, M., & Maggi, C. A. (1996). Role of kappa opioid receptors in modulating cholinergic twitches in the circular muscle of guinea-pig colon. British Journal of Pharmacology, 119, 985-989.
16. Goldstein, A., & Naidu, A. (1989). Multiple opioid receptors: Ligand selectivity profiles and binding site signatures. Molecular Pharmacology, 36, 265-272.
17. Hiramatsu, M.,Murai,M.,&Kameyama, T. (1999). Different modulation of cholinergic neuronal systems by dynorphin A (1-13) in carbon monoxide-exposed mice. Biochemical Pharmacology, 57, 1321-1329.
18. Hiramatsu, M., Murasawa, H., Mori, H., & Kameyama, T. (1998). Reversion of muscarinic autoreceptor agonist-induced acetylcholine decrease and learning impairment by dynorphin A (1-13), an endogenous kappa-opioid receptor agonist. British Journal of Pharmacology, 123, 920-926.
19. Hoffman, D. W., & Zamir, N. (1984). Localization and quantitation of dynorphin B in the rat hippocampus. Brain Research, 324, 354-357.
20. Huang, L. Y. M. (1995). Cellular mechanism of excitatory and inhibitory actions of opioids. In L. F. Tseng (ed.), The Pharmacology of Opioid Peptides. Amsterdam: Hardwood Academic Publishers, Gmbh, 131-149.
21. Jiang, H. K.,McGinty, J. F.,&Hong, J. S. (1990).Differential modulation of striatonigral dynorphin and enkephalin by dopamine receptor subtypes. Brain Research, 507, 57-64.
22. Justice, J. B. Jr. (1993). Quantitative microdialysis of neurotransmitters. Journal of Neuroscience Methods, 48, 263-276.
23. Khachaturian, H., Lewis,M. E.,&Watson, S. J. (1983). Colocalization of proenkephalin peptides in rat brain neurons. Brain Research, 279, 369-373.
24. Klitenick, M. A., & Wirtshafter, D. (1995). Behavioral and neurochemical effects of opioids in the paramediam midbrain tegmentum including the median raphe nucleus and ventral tegmental area. Journal of Pharmacology and Experimental Therapeutics, 273, 327-336.
25. Kow, L. M.,&Pfaff, D.W. (1988). Neuromodulatory actions of peptides. Annual Review of Pharmacoogy and Toxicology, 28, 163-188.
26. Lewis, M., Young, R. A., Houghten, H. A., & Watson, S. J. (1984). Binding of [3H] dynorphin A to apparent k opioid receptors in deep layers of guinea pig cerebral cortex. European Journal of Pharmacology, 98, 149.
27. Li, S., Sivam, S. P., & Hong, J. S. (1986). Regulation of the concentration of dynorphin A1-8 in the striatonigral pathway by the dopaminergic system. Brain Research, 398, 390-392.
28. Manzanares, J., Lookingland, K. J., & Moore, K. E. (1991). Kappa opioid receptormediated regulation of dopaminergic neurons in the rat brain. Journal of Pharmacology and Exerimental Therapeutics, 256, 500-505.
29. Martinka, G. P., Jhamandas, K., Sabourin, L., Lapierre, C., & Lemaire, S. (1991). DynorphinA-(1-13)-Tyr14-Leu-15-Phe16-Asn17-Gly18-Pro19: Apotent and selective ê opioid peptide. European Journal of. Pharmacology, 196, 161-167.
30. Meyer, J. S., & Quenzer, L. F. (2004). Psychopharmacology: Drugs, the Brain, and Behavior. Sunderland, Massachusetts: Sinauer Associates.
31. Mulder, A. H., Burger, D. M., Wardeh, G., Hogenboom, F., & Frankhuyzen, A. L. (1991). Pharmacological profile of various ê-agonists and ê, μ - and ä-opioid receptors mediating presynaptic inhibition of neurotransmitter release in rat brain. British Journal of Pharmacology, 102, 518-522.
32. Mulder, A. H., Wardeh, G., Hogenboom, F., & Frankhuyzen, A. L. (1984). Kappaand delta-opioid receptor agonists differentially inhibit striatal dopamine and acetylcholine release. Nature, 308, 278-280.
33. Mulder, A. H.,Wardeh, G., Hogenboom, F.,&Frankhuyzen, A. L. (1989). Selectivity of various opioid peptides towards delta-, kappa, and mu-opioid receptors mediating presynaptic inhibition of neurotransmitter release in the brain. Neuropeptides, 14, 99-104.
34. Nakayama, S., Taniyama, K.,Matsuyama, S., Ohgushi,N., Tsunekawa,K.,&Tanaka, C. (1990). Regulatory role of enteric mu and kappa opioid receptors in the release of acetylcholine and norepinephrine from guinea pig ileum. Journal of Pharmacology and Exerimental Therapeutics, 254, 792-798.
35. Nestler, E. J., & Aghajanian, G. K. (1997). Molecular and cellular basis of addiction. Science, 278, 58-63.
36. North, R. A. (1993). Opioid actions on membrane ion channels. In A. Herz, H. Akil, E. J. Simon, (eds.), Opioids I. Hand Book of Experimental Pharmacology. Berlin: Springer-Verlag, 773-798.
37. Oka, T.,Hegishi,K., Suda,M., Sawa,A., Fugino, M.,&Wakimasu, M. (1982). Evidence that dynorphin-(1-13) acts as an agonist on opioid k-receptors. European Journal of Pharmacology, 77, 137-141. (Pubitemid 12213600)
38. Pani, A. K., Matochik, J. A., & Shippenberg, T. S. (1997). Opioid and non-opioid fragments of dynorphin modulate the activity of mesostriatal dopamine neurons [Abstract]. Society for Neuroscience Abstracts, 23, 399.
39. Pani, A. K., & Shippenberg, T. S. (1997). Detection and quantification of dopamine and Serotonin by HPLC/EC. In J. N. Crawley, et al. (eds.), Current Protocols in Neuroscience. New York: John Wiley & Sons, 7.4.1-7.4.19.
40. Paxinos, G., &Watson, C. (1995). The Rat Brain in Stereotaxic Coordinates. NewYork: Academic Press.
41. Przewlocki, R. (1984). Some aspects of physiology and pharmacology of endogenous opioid peptides. Polish Journal of Pharmacology and Pharmacy, 36, 137-158.
42. Rady, J. J., & Fujimoto, J. M. (1993). Dynorphin A (1-17) mediates midazolam antagonism of morphine antinociception in mice. Pharmacology, Biochemistry and Behavior, 46, 331-339.
43. Reid, M. S., Herrera-Marschitz, M., Hokfelt, T., Lindefors, N., Persson, H., & Ungerstedt,U. (1990). Striatonigral GABA, dynorphin, substance P and neurokinin A modulation of nigrostriatal dopamine release: Evidence for direct regulatory mechanisms. Experimental Brain Research, 82, 293-303.
44. Schoffelmeer, A. N., De Vries, T. J., Hogenboom, F., & Mulder, A. H. (1993). Mu- and delta-opioid receptors inhibitory linked to dopamine-sensitive adenylate cyclase in rat striatum display a selectivity profile toward endogenous opioid peptides different from that of presynaptic mu, delta and kappa receptors. Journal of Pharmacology and Experimental Therapeutics, 267, 205-210.
45. Schoffelmeer, A. N., Hogenboom, F., & Mulder, A. H. (1997). Kappa1- and kappa2-opioid receptors mediating presynaptic inhibition of dopamine and acetylcholine release in rat neostriatum. British Journal of Pharmacology, 122, 520-524.
46. Siegel, G. J., Agranoff, B.W., Albers, R.W., Fisher, S. K., & Uhler, M. D. (1999). Basic Neurochemistry. Philadelphia, New York: Lippincott-Raven, 1-1183.
47. Simmons, M. L., & Chavkin, C. (1996). Endogenous opioid regulation of hippocampal function. International Review of Neurobiology, 39, 145-196.
48. Simon, E. J. (1987). Subunit structure and purification of opioid receptors. Journal of Receptor Research, 7, 105-132.
49. Siniscalchi, A., Bertelli, M. G., Bianchi, C., & Beani, L. (1990). Effect of opioid antagonists on acetylcholine release from guinea-pig slices: Influence of peptidase inhibition. Pharmacological. Research, 22, 493-501.
50. Sivam, S. P. (1989). Cocaine selectively increases striatonigral dynorphin levels by a dopaminergic mechanism. Journal of Pharmacology and Experimental Therapeutics, 250, 818-824.
51. Smith, A. P., & Lee, N. M. (1988). Pharmacology of dynorphin. Annual Review of Pharmacology and Toxicology, 28, 123-140.
52. Spanagel, R., Herz, A., & Shippenberg, T. S.,(1990). The effects of opioid peptides on dopamine release in the nucleus accumbens: An in vivo microdialysis study. Journal of Neurochemistry, 55, 1734-1740.
53. Steiner, H., & Gerfen, C. R. (1995). Dynorphin opioid inhibition of cocaine-induced, D1 dopamine receptor-mediated immediate-early gene expression in the striatum. Journal of Comparative Neurology, 353, 200-212.
54. Steiner, H., & Gerfen, C. R. (1998). Role of dynorphin and enkephalin in the regulation of striatal output pathways and behavior. Experimental Brain Research, 123, 60-76.
55. Terman, G. W., Drake, C. T., Simmons, M. L., Milner, T. A., & Chavkin, C. (2000). Opioid modulation of recurrent excitation in the hippocampal dentate gyrus. Journal of Neuroscience, 20, 4379-4388.
56. Thompson, A. C., & Shippenberg, T. S. (1997). Microdialysis in rodents. In J. N. Crawley et al. (eds.), Current Protocols in Neuroscience. New York: John Wiley & Sons, 7.2.1-7.2.28.
57. You, Z. B., Herrera-Marschitz, M., & Terenius, L. (1999). Modulation of neurotransmitter release in the basal ganglia of the rat brain by dynorphin peptides. Journal of Pharmacology and Experimental Therapeutics, 290, 1307-1315.